Employers need a voice at the table with health systems, hospitals, and carriers in shaping cancer care, according to Rosa ...

Technology, particularly artificial intelligence (AI), represents the biggest structural shift in oncology drug development over the past 5 years, according to David Spigel, MD, p ...

This interview has been lightly edited for clarity.

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill ...

Chronic hand eczema commonly reflects overlapping irritant, allergic, atopic, and protein-driven mechanisms, making patch ...

This commentary discusses the current prior authorization (PA) process and the negative impacts it can have on patient care. According to the American Medical Association, 94% of patients experience ...

Tampa General Hospital and Moffitt Cancer Center are both racing to expand outpatient capacity, from added observation bays ...

Employers can improve access to cancer care and address rising costs by pairing existing benefits with targeted strategies, ...

The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.

Advanced primary care may be one of employers' strongest tools for catching cancer earlier, and better support during and ...

Debra Patt, MD, PhD, MBA, MPH, discusses how AI can streamline prior authorization and revenue cycle workflows in community ...